*all presenters are MSH staff, unless otherwise noted
WEDNESDAY, OCTOBER 26
- Lessons learned from increasing access to Bedaquiline and Delamanid for management of drug resistance TB | 11:15-14:15, Session Room 7, ACC Liverpool
The purpose of this session will be to present and share preliminary lessons learned from selected countries that have accessed Bedaquiline and Delamanid through the GDF. This information is relevant as countries plan to introduce Bedaquiline and Delamanid.
- Digital health technology for the End TB Strategy: developing priority products and making them work | 14:45-17:45, Session Room 2, ACC Liverpool
Presenter: Niranjan Konduri
The End TB Strategy of the World Health Organization (WHO) projects to bring the TB epidemic in the world to an end in the 20 years after 2015. For this to happen, novel solutions will be needed to address the challenges posed by TB to health professionals and to affected people and communities. Information and communication technology present opportunities for innovative approaches to scale up the support to TB efforts in patient care, surveillance, program management and eLearning. In September 2015, WHO and the European Respiratory Society (ERS) jointly released a digital health ‘agenda for action’ for the End TB Strategy. This workshop will focus on how digital health innovations are supporting global efforts to improve TB care and prevention. As an output of this workshop, a short paper will be written and submitted for publication describing the progress in the development of target product profiles (TPPs) to work towards optimized solutions as well as case studies in countries applying some of these technologies. (PHT)
THURSDAY, OCTOBER 27
- Active TB drug safety monitoring and management: a transformative approach to limit treatment-related patient harm | 10:30-12:00, Session Room 8, ACC Liverpool
Presenter and Chair: Antonia Kwiecien, Presenter: Nino Lomtadze, SIAPS Consultant, Georgia
Reporting adverse events (AEs) from real-life clinical practice contributes to evidence for decision making that impacts prescribing practices and improves treatment safety. In 2015, the World Health Organization launched the active drug safety monitoring management (aDSM) strategy. The strategy aims to promote the safe use of new TB medicines and novel regimens and develop a robust safety database to proactively protect public health.
- Tuberculosis and diabetes collaborative activities in the context of the End TB Strategy and Sustainable Development Goals | 13:30-14:45, Session Room 1, ACC Liverpool
Presenter and Chair: Rudi Thetard
There is substantial evidence on the feasibility of integrating services for TB and diabetes mellitus (DM) in settings with dual burden of the two diseases. However, there is limited implementation experience at a larger scale.
Our objectives are to:
- Describe progress, barriers and challenges in the implementation of TB-DM collaborative activities
- Share promising country experiences in translating global recommendations on integrating TB and diabetes care into action
- Identify effective models of integration in resource-constrained settings with dual burden of TB and non-communicable diseases
- To discuss the way forward in implementing TB-DM collaborative activities, including unanswered research questions.
Using TB and HIV platforms for prevention and control of diabetes mellitus: successful example from Ethiopia |14:15-14:30, Session Room 1, ACC Liverpool
Presenter: Degu Jerene
FRIDAY, OCTOBER 28
- Challenging Tuberculosis in Urban Settings and Big Cities in African, Euro-Asian and Latin American countries | 10:30-12:00, Session Room 1C, ACC Liverpool
Presenter and Chair: Pedro Suarez
The world’s total urban population reached an estimated 3.8 billion in 2013, and is projected to swell to nearly 6.3 billion by 2050. In 2015, the urban population represented over half of the global population compared to about a third in 1960. During the last two decades, TB incidence has increased in urban settings and big cities as a result of several social and demographic factors, including poor TB control efforts and the rise and concentration of high-risk groups.
Addressing the TB control issue in fragile states: urban DOTS experience in Kabul, Afghanistan | 10:45-11:00, Session Room 1C, ACC Liverpool
Presenter: Mohammad Rashidi
- MDR-TB and XDR-TB treatment service delivery models in African and Latin American countries | 13:30-15:00, Session Room 3B, ACC Liverpool
Presenter: Raymond Byaruhanga
Multi Drug Resistant (MDR) and extensively-drug resistant TB (XDR-TB) are global challenges. Centralized inpatient treatment is still a common practice in many MDR-TB high-burden countries, but the lack of hospitals, long waiting lists for admissions, and high hospitalization costs present challenges. Long hospital stays also disrupt patients’ livelihoods and may result in catastrophic costs. Hospitals are not linked to the primary health care centers in many cases and as a result there is no tracing mechanism to ensure proper follow-up. WHO recommends ambulatory models of care and treatment over hospital-based models.
- Early warning system to improve patient access to TB medicines: from quantification to decision making | 13:30-15:00, Session Room 1B, ACC Liverpool
Presenter and Chair: Luis Gustavo do Valle Bastos
Ensuring that patients have continuous access to TB treatment requires complex calculations. Making projections is becoming more challenging with the introduction of new drugs and regimens and the phase-out of other regimens. Frequent forecasting and quantification, along with vigilant stock management, are vital to ensuring that appropriate types and quantities of medicines are available for treatment of all patients. Speakers will discuss early warning system (EWS) for TB medicines including second-line and pediatric drugs. Data from QuanTB tool as an EQS for drug stock-outs and experiences in high burden countries in Africa and Asia will be presented.
SATURDAY, OCTOBER 29
- TB elimination initiative in countries of Latin America Region | 10:30-12:00, Session Room 1C, ACC Liverpool
Presenters and Chairs: Pedro G Suarez, and Rafel Lope Olarte, PAHO, WHO
There is heterogeneity in the distribution of tuberculosis (TB) incidence rates among countries of the Americas, from over 200 cases to less than 10 cases per 100,000 population. A group of low-incidence countries in the Latin America (LA) Region was constituted in 2000, including Chile, Costa Rica, Cuba, Uruguay and Venezuela as observer. In 2010, the united States, Canada and Puerto Rico were invited to join. The group aims to adapt TB control measures to these contexts, exchange North-South and South-South experiences, and develop a TB elimination plan aligned with WHO’s framework for TB elimination in low-incidence countries.
- Biosafety and Tuberculosis Infection Control: Sharing knowledge, challenges & solutions in TB laboratories | 10:30-12:00, Session Room 11A, ACC Liverpool
Presenter and Chair: Alaine Umubyeyi Nyaruhirira
Biosafety in TB laboratories varies widely. Significant investment has been made in infrastructure upgrades, particularly at reference laboratory levels. Many countries have unsafe working environments (microscopy/Xpert to culture to DST). Even where upgraded, adequate operation and maintenance of biosafety equipment (BSCs, centrigures, HVAC systems), and provision of PPE (respirators, gloves, etc.) is lacking. This session will highlight effective approaches to solving issues that laboratories face and demonstrate synergy of biosafety with infection control. Target audience: Clinicians, laboratorians, national TB program staff, and Ministry of Health officials, maintenance experts, biosafety professionals, or service and lab managers.